{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:29:52Z","timestamp":1792682992057,"version":"4.5.0"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec><jats:label\/><jats:p>Midkine is a multifunctional factor and has anti\u2010apoptotic, migration\u2010promoting, angiogenic, anti\u2010microbial and other activities. Midkine ameliorates ischemic injury in the heart and brain, enhances oocyte maturation, and is involved in neurogenesis. On the other hand, midkine is an important factor in the etiology of various diseases, especially those with inflammatory backgrounds. Furthermore, midkine is overexpressed in most malignant tumors and plays roles in their invasive phenotypes as well as in their resistance to chemotherapeutics. Therefore, midkine itself is expected to be useful for the treatment of brain and heart diseases, while midkine inhibitors are promising for the treatment of malignant tumors, multiple sclerosis, restenosis, renal diseases, hypertension and osteoporosis. Blood levels of midkine are also expected to be helpful as disease markers, especially as cancer markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Linked Articles<\/jats:title><jats:p>This article is part of a themed section on Midkine. To view the other articles in this section visit <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1111\/bph.2014.171.issue-4\">http:\/\/dx.doi.org\/10.1111\/bph.2014.171.issue\u20104<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1111\/bph.12571","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T16:41:28Z","timestamp":1390581688000},"page":"811-813","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Midkine: an emerging target of drug development for treatment of multiple diseases"],"prefix":"10.1111","volume":"171","author":[{"given":"Takashi","family":"Muramatsu","sequence":"first","affiliation":[{"name":"Department of Health Science Faculty of Psychological and Physical Science Aichi Gakuin University  12 Araike, Iwasaki\u2010cho, Nisshin Aichi 470\u20100195 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kadomatsu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Nagoya University Graduate School of Medicine  65 Tsurumai\u2010cho, Showa\u2010ku Nagoya 466\u20108550 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12419"},{"key":"e_1_2_3_3_1","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-4234-5","volume-title":"Midkine: from embryogenesis to pathogenesis and therapy","author":"Erguven M","year":"2012"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12402"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12495"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12401"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12312"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12311"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12537"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12442"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12412"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795164167"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12353"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12418"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12499"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12462"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12497"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbph.12571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.12571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:26:01Z","timestamp":1694633161000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.12571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/bph.12571"],"URL":"https:\/\/doi.org\/10.1111\/bph.12571","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]},"assertion":[{"value":"2014-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}